CXCL9 and neoplasm: In summary, these findings demonstrate that in preclinical PDAC models silencing of Gsdmc unleashes CXCL9 as a key downstream mechanism for the TME‐modulating effects of GSDMC, resulting in an uprise of tumor‐infiltrating immune cells and a subsequent reversal of tumor progression.